Hutchmed (China) (HCM) revenue and earnings history
Hutchmed (China) reported revenue of $549M for fiscal 2025 (year ended Dec 31, 2025), −13.0% on the year before, and net income of $457M.
Over 11 years, from fiscal 2014 to fiscal 2025, revenue grew at a compound rate of +18.2% a year.
Revenue and net income, 12 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $549M−13.0% | −$39.2M | $457M | −$64.7M | $14.1M | −$78.8M | — | — | — | $71.3M | $93.2M | 20-F |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Hutchmed (China) (HCM) on OQRO.
Common questions
What was Hutchmed (China)'s revenue in fiscal 2025?
$549M for the year ended Dec 31, 2025, as reported in its 20-F filed Mar 5, 2026. That is −13.0% on fiscal 2024 ($630M).
How fast has Hutchmed (China)'s revenue grown?
From $87.3M in fiscal 2014 to $549M in fiscal 2025: a compound annual growth rate of +18.2% over 11 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Where these figures come from
The SEC’s companyfacts data: every figure Hutchmed (China) tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.